|
Discovery of Novel Wnt Inhibitors and Uses Thereof
Canonical WNT (Wingless/integrase 1) signaling is an important developmental pathway that has attracted increased attention for anti-cancer drug discovery. Researchers at the University of Arizona are investigating utility for the compounds herein for the treatment of colorectal cancer as well as potential disease modifying agents for the treatment...
Published: 11/14/2024
|
Inventor(s): Christopher Hulme, Sammantha Rokey, Yeng Jeng Shaw, Curtis Thorne, Timothy Chavez, Carly Cabel, Nathan Bedard, Sourav Banerjee
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios
|
|
Small Molecule DYRK/CLK Inhibitors and Uses Thereof
This invention is a new composition of matter spanning a 6,6-fused chemotype. The 6,6-analogs display strong inhibitory activity across protein kinases such as the DYRK family, including DYRK1A, DYRK2, and DYRK3, along with inhibiting CLK. The dual DYRK/CLK inhibitors have displayed activity in 3-D organoid models of glioblastoma. It is subsequently...
Published: 11/14/2024
|
Inventor(s): Christopher Hulme, Alessandra Fistrovich, Yeng Jeng Shaw, Sourav Banerjee, Curtis Thorne, Nathan Bedard, Carly Cabel
Keywords(s):
Category(s): Technology Classifications, Technology Classifications > Healthcare Portfolios
|
|
2-Aryl-Pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer
University of Arizona researchers have identified two potent small molecules that target a common mutation found in pancreatic cancer cells with high specificity and induce cell death. These compounds are genotype specific for the DPC4 mutation associated with cancer phenotypes and, compared to available treatments, are significantly more potent and...
Published: 11/16/2023
|
Inventor(s): Robert Dorr, Gary Flynn, Haiyong Han, Meredith Henderson, Laurence Hurley, Yeng Jeng Shaw, Daniel Von Hoff
Keywords(s):
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Small Molecules
|
|
Novel Inhibitors of the Androgen Receptor for the Treatment of Castration Resistant Prostate Cancer (CRPC)
This invention is a new class of heterocyclic small-molecules designed to antagonize the androgen receptor. These molecules have promising biological activity in a prostate specific cell line.
Background:
The primary method for treating early stage prostate cancer is via androgen deprivation therapy because prostate cancer needs androgen in order...
Published: 11/16/2023
|
Inventor(s): Christopher Hulme, Yeng Jeng Shaw, Vijay Gokhale
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics
|
